Before joining Opsona Therapeutics, Martin Welschof was the Managing Director and co-founder of Affitech A/S, a biopharmaceutical company listed on the Nasdaq OMX Copenhagen stock exchange. Affitech A/S is a human antibody company with product focus primarily in cancer and inflammation and having proprietary technologies in the discovery and early stage development of human antibodies. Prior to joining Affitech A/S, Martin Welschof was the Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, which he joined in 1997 during its start-up phase. From 1999 until 2002 he led Axaron’s technology department and was responsible for the R&D process related to a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics. During that time he worked at Axaron’s parent company, LYNX Therapeutics Inc., Hayward, California, where he coordinated the process development of LYNX massive parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS. Martin Welschof did his post-doctoral training at the German Cancer Research Center's Department for Recombinant Antibody Technology and the University of Heidelberg's Department of Transplantation Immunology, both in Heidelberg, Germany (1996 to 1997). He has a Ph.D. (Dr.rer.nat.) in the field of recombinant antibody technology from the University of Bielefeld, Germany.
transcription analysis and functional genomics